Evaluating Thera-101 as a Low Volume Resuscitation Adjunct in a Model of Traumatic Brain Injury and Hemorrhage

Traumatic brain injury (TBI) and hemorrhage remain challenging to treat in austere conditions. Developing a therapeutic to mitigate the associated pathophysiology is critical to meet this treatment gap, especially as these injuries and associated high mortality are possibly preventable. Here, Thera-101 (T-101) was evaluated as an adjunct to low volume resuscitation in a rat model of TBI and hemorrhage. The therapeutic, T-101, is uniquely situated as a TBI and hemorrhage intervention. It contains a cocktail of proteins and microvesicles from the secretome of adipose derived mesenchymal stem cells that can act on numerous mechanisms associated with poly-trauma. T-101 efficacy was determined at four, 24, 48, and 72 hours after injury by evaluating blood chemistry, inflammatory chemo/cytokines, histology, and diffusion tensor imaging. Blood chemistry indicated that T-101 reduces markers of liver damage to Sham levels while the levels remain elevated with the vehicle control. Histology supports the potential protective effects of T-101 on the kidneys. Diffusion tensor imaging shows that the injury caused the most damage to the corpus callosum and the fimbria. Immunohistochemistry suggests that T-101 may mitigate astrocyte activation at 72 hours. Together, these data suggest T-101 could be a potential field deployable adjunct for low volume resuscitation.